Diagnostic Center | April 15, 2024
Teva confirms efficacy and safety of Ajovy for prevention of migraine
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)